Cancer immunotherapy has now entered clinical practice and has reshaped the standard of
care for many cancer patients. With these new strategies, specific toxicities have emerged …

Chimeric antigen receptor (CAR) T-cell therapy is novel immunotherapy targeting
specifically cancerous cells, and has been shown to induce durable remissions in some …

Chimeric antigen receptor (CAR) T cell therapy is a revolutionary form of immunotherapy
that has proven to be efficacious in the treatment of many hematologic cancers. CARs are …

Chimeric antigen receptor T (CAR-T)-cell, an adaptive immune therapy is approved for
patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Its use and …

Cancer treatment is one of the fundamental challenges in clinical setting, especially in
relapsed/refractory malignancies. The novel immunotherapy-based treatments bring new …

The majority of podocyte disorders are progressive in nature leading to chronic kidney
disease and often kidney failure. The scope of current therapies is typically nonspecific …

Abstract The 14th International Podocyte Conference took place in Philadelphia, USA, from
May 23rd to 26th, 2023. It commenced with an early-career researchers' meeting on May …

CAR T-cell therapy and the onco-nephrologist Page 1 CAR T-cell therapy and the onco-nephrologist
Marco Aurelio Salvino1,2,3*, Alberto Mussetti2, Marta Peña2, Annalisa Paviglianiti2, Abel …

Introduction Acute kidney injury (AKI) frequently develops in patients receiving cancer
therapy and requires a wide differential diagnosis due to possible role of unique cancer and …

Background Acute kidney injury (AKI) has been reported after CAR-T cells, but available
data are limited. We sought to describe the incidence of AKI in a cohort of patients …